The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1455
Two New GLP-1 Receptor Agonists for Diabetes
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Two new injectable GLP-1 (glucagon-like peptide-1) receptor agonists, dulaglutide (Trulicity [trū li si tee] – Lilly) and albiglutide (Tanzeum [tan' zee um] – GSK), have been approved by the FDA for once-weekly treatment of type 2 diabetes. Other available GLP-1 receptor agonists include exenatide, which is approved for injection twice daily (Byetta) or once weekly (Bydureon), and liraglutide (Victoza), which is injected once daily.

GLP-1 RECEPTOR AGONISTS — When metformin alone fails to control hyperglycemia, addition of a GLP-1 receptor agonist is an option. These drugs are less likely than sulfonylureas or insulin to cause hypoglycemia and usually cause weight loss, but they are expensive and long-term safety data are lacking.1

Mechanism of Action – Released by cells in the gastrointestinal tract in response ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Two New GLP-1 Receptor Agonists for Diabetes
Article code: 1455a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian